ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 75.1 | 94.8 | 89.1 |
| Other income | 2.0 | 0.2 | 2.3 |
| Total income | 77.2 | 95.0 | 91.5 |
| Profit before exceptional items & tax | 0.9 | 8.8 | 3.9 |
| Profit before tax | 0.9 | 8.8 | 3.9 |
| Net profit | 0.3 | 6.6 | 3.5 |
| Operating margin | 1.2% | 9.3% | 4.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -91.40% |
|---|---|
| Net profit, quarter on quarter | -95.50% |
| Revenue, year on year | -15.70% |
BSE results filing, NSE: HALEOSLABS. Figures extracted from the filing.
Haleos Labs Ltd: key numbers
- Share price
- ₹1,422.40
- Market cap
- ₹430.0 Cr
- Revenue (annual)
- ₹333.8 Cr
- Net profit (annual)
- ₹17.31 Cr
- P/E (TTM)
- 33.2×Sector 43.8×
- Promoter holding
- 72.11%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Haleos Labs Ltd
All →Haleos Labs Q2 FY27 Results: Net Profit ₹1.8 Cr, Down 71.9% YoY
Haleos Labs Ltd reported revenue from operations of ₹91.4 Cr (+12.3% YoY) and net profit of ₹1.8 Cr (-71.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.8 Cr · -71.9% YoY
Haleos Labs Board Meeting Date
Haleos Labs scheduled its 99th board meeting for November 11, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The trading window stays closed until November 13, 2026.
Haleos Labs Other Announcement
Haleos Labs withheld FY2025-26 dividend for shareholders who have not updated KYC or bank details. Notices were sent to affected shareholders on 31 October 2026 pending compliance.
Haleos Labs Annual General Meeting
Haleos Labs Limited conducted its 20th Annual General Meeting on September 30, 2026. The meeting discussed financial statements, dividend declaration, and various director reappointments.
Haleos Labs Business Update
USFDA inspected the material subsidiary Mahi Drugs' API facility in Parawada. The inspection concluded with zero Form 483 observations.
Haleos Labs Other Announcement
Haleos Labs Ltd notified shareholders of the Annual Report and AGM notice weblink, while requesting updates to their KYC and email addresses.